These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 32060866)

  • 1. Oral Yohimbine as a New Probe Drug to Predict CYP2D6 Activity: Results of a Fixed-Sequence Phase I Trial.
    Vay M; Meyer MJ; Blank A; Skopp G; Rose P; Tzvetkov MV; Mikus G
    Clin Pharmacokinet; 2020 Jul; 59(7):927-939. PubMed ID: 32060866
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of Hydroxychloroquine as a Perpetrator on Cytochrome P450 (CYP) 3A and CYP2D6 Activity with Microdosed Probe Drugs in Healthy Volunteers.
    Stoll F; Blank A; Mikus G; Czock D; Weiss J; Meyer-Tönnies MJ; Gümüs KS; Tzvetkov M; Burhenne J; Haefeli WE
    Eur J Drug Metab Pharmacokinet; 2024 Jan; 49(1):101-109. PubMed ID: 38114885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploring the relationship between expression of cytochrome P450 enzymes and gefitinib pharmacokinetics.
    Swaisland HC; Cantarini MV; Fuhr R; Holt A
    Clin Pharmacokinet; 2006; 45(6):633-44. PubMed ID: 16719544
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of CYP2C19 activity using microdosed oral omeprazole in humans.
    Elbe A; Foerster KI; Blank A; Rose P; Burhenne J; Haefeli WE; Mikus G
    Eur J Clin Pharmacol; 2022 Jun; 78(6):975-987. PubMed ID: 35238961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Time Course of the Interaction Between Oral Short-Term Ritonavir Therapy with Three Factor Xa Inhibitors and the Activity of CYP2D6, CYP2C19, and CYP3A4 in Healthy Volunteers.
    Rohr BS; Krohmer E; Foerster KI; Burhenne J; Schulz M; Blank A; Mikus G; Haefeli WE
    Clin Pharmacokinet; 2024 Apr; 63(4):469-481. PubMed ID: 38393578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in the QTc interval after administration of flecainide acetate, with and without coadministered paroxetine, in relation to cytochrome P450 2D6 genotype: data from an open-label, two-period, single-sequence crossover study in healthy Korean male subjects.
    Lim KS; Jang IJ; Kim BH; Kim J; Jeon JY; Tae YM; Yi S; Eum S; Cho JY; Shin SG; Yu KS
    Clin Ther; 2010 Apr; 32(4):659-66. PubMed ID: 20435235
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Contribution of cytochrome P450 2D6 to 3,4-methylenedioxymethamphetamine disposition in humans: use of paroxetine as a metabolic inhibitor probe.
    Segura M; Farré M; Pichini S; Peiró AM; Roset PN; Ramírez A; Ortuño J; Pacifici R; Zuccaro P; Segura J; de la Torre R
    Clin Pharmacokinet; 2005; 44(6):649-60. PubMed ID: 15910012
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytochrome P450 2D6 genotype affects the pharmacokinetics of controlled-release paroxetine in healthy Chinese subjects: comparison of traditional phenotype and activity score systems.
    Chen R; Wang H; Shi J; Shen K; Hu P
    Eur J Clin Pharmacol; 2015 Jul; 71(7):835-41. PubMed ID: 25967538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Absolute oral bioavailability of traxoprodil in cytochrome P450 2D6 extensive and poor metabolisers.
    Taylor TJ; Diringer K; Russell T; Venkatakrishnan K; Wilner K; Crownover PH; Benincosa LJ; Gibbs MA
    Clin Pharmacokinet; 2006; 45(10):989-1001. PubMed ID: 16984212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Phase I, Open-Label, Fixed Sequence Study to Investigate the Effect of Cytochrome P450 2D6 Inhibition on the Pharmacokinetics of Ulotaront in Healthy Subjects.
    Tsukada H; Chen YL; Xiao G; Lennek L; Milanovic SM; Worden M; Polhamus DG; Chiu YY; Hopkins SC; Galluppi GR
    Clin Pharmacokinet; 2023 Dec; 62(12):1755-1763. PubMed ID: 37882999
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of paroxetine on the pharmacokinetics of atomoxetine and its metabolites in different CYP2D6 genotypes.
    Jung EH; Lee YJ; Kim DH; Kang P; Lim CW; Cho CK; Jang CG; Lee SY; Bae JW
    Arch Pharm Res; 2020 Dec; 43(12):1356-1363. PubMed ID: 33245517
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CYP3A and CYP2C19 Activity Determined by Microdosed Probe Drugs Accurately Predict Voriconazole Clearance in Healthy Adults.
    Muhareb A; Blank A; Meid AD; Foerster KI; Stoll F; Burhenne J; Haefeli WE; Mikus G
    Clin Pharmacokinet; 2023 Sep; 62(9):1305-1314. PubMed ID: 37505445
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of cytochrome P450 2D6 genotype on maternal paroxetine plasma concentrations during pregnancy.
    Ververs FF; Voorbij HA; Zwarts P; Belitser SV; Egberts TC; Visser GH; Schobben AF
    Clin Pharmacokinet; 2009; 48(10):677-83. PubMed ID: 19743889
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Physiologically Based Pharmacokinetic Modelling to Describe the Pharmacokinetics of Risperidone and 9-Hydroxyrisperidone According to Cytochrome P450 2D6 Phenotypes.
    Kneller LA; Abad-Santos F; Hempel G
    Clin Pharmacokinet; 2020 Jan; 59(1):51-65. PubMed ID: 31359271
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of the novel anxiolytic drug deramciclane on cytochrome P(450) 2D6 activity as measured by desipramine pharmacokinetics.
    Laine K; De Bruyn S; Björklund H; Rouru J; Hänninen J; Scheinin H; Anttila M
    Eur J Clin Pharmacol; 2004 Feb; 59(12):893-8. PubMed ID: 14730412
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantification of microdosed oral yohimbine and its major metabolite in human plasma in the picogram range.
    Vay M; Sauter M; Mikus G; Burhenne J
    Bioanalysis; 2019 Aug; 11(16):1459-1467. PubMed ID: 31411489
    [No Abstract]   [Full Text] [Related]  

  • 17. Pharmacokinetic interaction of flecainide and paroxetine in relation to the CYP2D6*10 allele in healthy Korean subjects.
    Lim KS; Cho JY; Jang IJ; Kim BH; Kim J; Jeon JY; Tae YM; Yi S; Eum S; Shin SG; Yu KS
    Br J Clin Pharmacol; 2008 Nov; 66(5):660-6. PubMed ID: 18754843
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo.
    Gorski JC; Huang SM; Pinto A; Hamman MA; Hilligoss JK; Zaheer NA; Desai M; Miller M; Hall SD
    Clin Pharmacol Ther; 2004 Jan; 75(1):89-100. PubMed ID: 14749695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I open-label study to investigate the potential drug-drug interaction between single-dose dacomitinib and steady-state paroxetine in healthy volunteers.
    Ruiz-Garcia A; Giri N; LaBadie RR; Ni G; Boutros T; Richie N; Kocinsky HS; Checchio TM; Bello CL
    J Clin Pharmacol; 2014 May; 54(5):555-62. PubMed ID: 24293056
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of CYP2D6 genotype on exposure and efficacy of risperidone and aripiprazole: a retrospective, cohort study.
    Jukic MM; Smith RL; Haslemo T; Molden E; Ingelman-Sundberg M
    Lancet Psychiatry; 2019 May; 6(5):418-426. PubMed ID: 31000417
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.